Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


01.10.2018

2 Br J Dermatol
1 Cutis
2 J Am Acad Dermatol
1 J Clin Invest
1 J Immunol
3 J Surg Oncol
3 Melanoma Res
3 Oncogene
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Br J Dermatol

  1. KOREKAWA A, Akasaka E, Rokunohe D, Fukui T, et al
    Nagashima-type palmoplantar keratoderma and malignant melanoma in Japanese patients.
    Br J Dermatol. 2018 Sep 26. doi: 10.1111/bjd.17251.
    PubMed     Text format     Abstract available

  2. ROGIERS A, Thomas D, Vander Borght S, van den Oord JJ, et al
    Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
    Br J Dermatol. 2018 Sep 24. doi: 10.1111/bjd.17250.
    PubMed     Text format     Abstract available


    Cutis

  3. SUKHNANDAN F, Kahn MR, Bhattacharjee P
    Nonmalignant cutaneous findings associated with vemurafenib.
    Cutis. 2018;101:E2-E4.
    PubMed     Text format    


    J Am Acad Dermatol

  4. BRUNSSEN A, Jansen L, Eisemann N, Waldmann A, et al
    A population-based registry study on relative survival from melanoma in Germany stratified by tumor thickness for each histological subtype.
    J Am Acad Dermatol. 2018 Sep 19. pii: S0190-9622(18)32599.
    PubMed     Text format     Abstract available

  5. WEE E, Wolfe R, Mclean C, Kelly JW, et al
    Clinically amelanotic or hypomelanotic melanoma: Anatomic distribution, risk factors, and survival.
    J Am Acad Dermatol. 2018;79:645-651.
    PubMed     Text format     Abstract available


    J Clin Invest

  6. HUBER V, Vallacchi V, Fleming V, Hu X, et al
    Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma.
    J Clin Invest. 2018 Sep 27. pii: 98060. doi: 10.1172/JCI98060.
    PubMed     Text format     Abstract available


    J Immunol

  7. BADAMCHI-ZADEH A, Moynihan KD, Larocca RA, Aid M, et al
    Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy.
    J Immunol. 2018 Sep 24. pii: jimmunol.1800885. doi: 10.4049/jimmunol.1800885.
    PubMed     Text format     Abstract available


    J Surg Oncol

  8. BHUTIANI N, Egger ME, Stromberg AJ, Gershenwald JE, et al
    A model for predicting low probability of nonsentinel lymph node positivity in melanoma patients with a single positive sentinel lymph node.
    J Surg Oncol. 2018 Sep 27. doi: 10.1002/jso.25193.
    PubMed     Text format     Abstract available

  9. NUNES LF, Mendes GLQ, Koifman RJ
    Subungual melanoma: A retrospective cohort of 157 cases from Brazilian National Cancer Institute.
    J Surg Oncol. 2018 Sep 27. doi: 10.1002/jso.25242.
    PubMed     Text format     Abstract available

  10. RONCATI L, Piscioli F
    Clinical decision-making in patients with different histogenetic subtypes of thin melanoma.
    J Surg Oncol. 2018 Sep 27. doi: 10.1002/jso.25200.
    PubMed     Text format    


    Melanoma Res

  11. YIP RHL, Lee LH, Schaeffer DF, Horst BA, et al
    Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Melanoma Res. 2018 Sep 25. doi: 10.1097/CMR.0000000000000502.
    PubMed     Text format     Abstract available

  12. YIN G, Guo W, Chen X, Huang Z, et al
    Prognosis of endoscopic surgery and traditional open resection in mucosal melanoma of the nasal cavity and paranasal sinus.
    Melanoma Res. 2018 Sep 25. doi: 10.1097/CMR.0000000000000516.
    PubMed     Text format     Abstract available

  13. GHATE S, Ionescu-Ittu R, Burne R, Ndife B, et al
    Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.
    Melanoma Res. 2018 Sep 21. doi: 10.1097/CMR.0000000000000504.
    PubMed     Text format     Abstract available


    Oncogene

  14. TURNER JA, Bemis JGT, Bagby SM, Capasso A, et al
    BRAF fusions identified in melanomas have variable treatment responses and phenotypes.
    Oncogene. 2018 Sep 25. pii: 10.1038/s41388-018-0514.
    PubMed     Text format     Abstract available

  15. LECLERC J, Garandeau D, Pandiani C, Gaudel C, et al
    Lysosomal acid ceramidase ASAH1 controls the transition between invasive and proliferative phenotype in melanoma cells.
    Oncogene. 2018 Sep 25. pii: 10.1038/s41388-018-0500.
    PubMed     Text format     Abstract available

  16. KLUG LR, Bannon AE, Javidi-Sharifi N, Town A, et al
    LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma.
    Oncogene. 2018 Sep 21. pii: 10.1038/s41388-018-0508.
    PubMed     Text format     Abstract available


    PLoS One

  17. MARCHETTI CAUTELA J, Mannocci A, Reggiani C, Persechino F, et al
    Identifying the factors that influence surgeon's compliance with excisional margins of non-melanoma skin cancer.
    PLoS One. 2018;13:e0204330.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: